Table 1 Clinical features of enrolled patients.

From: Early modifications of the gut microbiome in children with hepatic sinusoidal obstruction syndrome after hematopoietic stem cell transplantation

ID

Age at HSCT, years

Time from diagnosis to HSCT, years

Time from last hospitalization, days

Gender

Diagnosis

Complete remission at transplant

Conditioning regimen (ATG)

Source of HSC

Type of Transplant

VOD

Day of VOD diagnosis

VOD grade

BSI (day)

GvHD grade (day)

EN

#1

16.6

0.3

108

M

MDS

No

BUS + EDX + L-PAM (ATG)

PBSC

MUD

Yes

10

3

No

I (+ 20)

No

#2

8.5

0.8

51

F

ALL

1st CR

BUS + THIO + EDX (ATG)

BM

MUD

Yes

19

3

No

 

Yes

#3

14.3

2.3

n.e.

F

ALL

2nd CR

BUS + THIO + EDX (ATG)

BM

MUD

Yes

18

4

No

 

Yes

#4

9.3

10.0

11

F

TM

No

BUS + THIO + FLUDA (ATG)

BM

MUD

Yes

17

4

E. coli (+ 8)

 

No

#5

5.5

2.5

109

M

ALL

2nd CR

THIO + TREO + FLUDA

BM

Haploidentical

Yes

26

4

No

III–IV (+ 22)

No

#6

18.2

0.5

19

M

AML

1st CR

BUS + EDX + L-PAM (ATG)

PBSC

MUD

Yes

21

3

No

 

Yes

#7

3.0

0.8

69

F

MDS

No

BUS + EDX + L-PAM (ATG)

BM

MUD

Yes

15

4

No

 

Yes

#8

1.0

0.4

5

F

ALL

1st CR

BUS + THIO + EDX

BM

MFD

Yes

15

4

No

II (+ 35)

No

#9

1.3

0.4

13

M

AML

1st CR

BUS + EDX + L-PAM

BM

MFD

Yes

25

3

No

 

No

#10

4.6

0.8

32

F

ALL

2nd CR

BUS + THIO + EDX (ATG)

BM

MUD

No

  

No

 

Yes

#11

20.6

0.8

93

M

ALL

1st CR

BUS + THIO + EDX (ATG)

BM

MUD

No

  

No

II (+ 15)

No

#12

8.1

5.2

15

M

ALL

3rd CR

BUS + THIO + FLUDA

BM

Haploidentical

No

  

No

 

Yes

#13

10.5

3.8

133

F

AML

2nd CR

THIO + TREO + FLUDA

BM

MFD

No

  

S. epidermidis, E. faecalis (+ 6)

 

No

#14

15.9

1.2

18

F

AML

2nd CR

BUS + THIO + FLUDA

BM

Haploidentical

No

  

No

II (+ 36)

Yes

#15

0.9

0.6

69

F

ALL

1st CR

BUS + THIO + EDX (ATG)

BM

MUD

No

  

E. coli (+ 2)

 

No

#16

6.0

4.4

12

M

TM

No

BUS + THIO + FLUDA (ATG)

BM

MUD

No

  

No

II (+ 26)

No

#17

14.4

0.3

48

F

AML

2nd CR

BUS + EDX + L-PAM (ATG)

BM

MUD

No

  

E. coli, E. faecium, S. warneri (+ 5)

I (+ 23)

Yes

#18

2.2

0.4

150

F

JMML

No

BUS + EDX + L-PAM (ATG)

BM

MUD

No

  

S. epidermidis, S. vestibularis (+ 36)

I (+ 35)

Yes

  1. ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, BM bone marrow, BSI blood stream infections, BUS busulfan, CR complete remission, EDX cyclophosphamide, EN enteral nutrition, FLUDA fludarabine, GvHD graft versus host disease, HSC hematopoietic stem cell, HSCT hematopoietic stem cell transplantation, JMML juvenile myelomonocytic leukemia, L-PAM melphalan, MDS myelodysplastic syndrome, MFD matched familiar donor, MUD matched unrelated donor, PBSC peripheral blood stem cells, THIO thiotepa, TM thalassemia major, VOD veno-occlusive disease. Patient’s matching was performed as following: #1–#17; #2–#14; #3–#12; #4–#16; #5–#13; #6–#11; #7–#10; #8–#15; #9–18.